KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biomarin Pharmaceutical (BMRN) Income from Continuing Operations (2017 - 2025)

Biomarin Pharmaceutical (BMRN) has disclosed Income from Continuing Operations for 16 consecutive years, with 46573000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Income from Continuing Operations fell 137.28% year-over-year to 46573000.0, compared with a TTM value of 348901000.0 through Dec 2025, down 18.26%, and an annual FY2025 reading of 348901000.0, down 18.26% over the prior year.
  • Income from Continuing Operations was 46573000.0 for Q4 2025 at Biomarin Pharmaceutical, down from 30744000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 240532000.0 in Q2 2025 and bottomed at 57898000.0 in Q4 2021.
  • Average Income from Continuing Operations over 5 years is 51044300.0, with a median of 34021000.0 recorded in 2022.
  • The sharpest move saw Income from Continuing Operations plummeted 440.02% in 2021, then skyrocketed 8282.73% in 2023.
  • Year by year, Income from Continuing Operations stood at 57898000.0 in 2021, then soared by 99.57% to 249000.0 in 2022, then surged by 8282.73% to 20375000.0 in 2023, then soared by 513.22% to 124943000.0 in 2024, then tumbled by 137.28% to 46573000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for BMRN at 46573000.0 in Q4 2025, 30744000.0 in Q3 2025, and 240532000.0 in Q2 2025.